If only people had listened six years ago to pharmacologist Garret FitzGerald.
Even as the drugs were launched, Garret FitzGerald, a researcher at the University of Pennsylvania, warned that they might be linked to heart problems.
Garret FitzGerald, a pharmacologist at the University of Pennsylvania, said that he thought the move would help recapture the lost value of the drug to some patients.
"We know that it causes problems from placebo-controlled trials, " says Garret FitzGerald, a pharmacologist at the University of Pennsylvania, who predicted early on there might be a risk with Cox-2 drugs.
But in 1999, the year Vioxx hit pharmacy shelves, a University of Pennsylvania scientist named Garret FitzGerald was already arguing that blocking only Cox-2 might raise the risk of heart attack and stroke.
Garret FitzGerald, the University of Pennsylvania pharmacologist who was a critic of the COX-2 inhibitors but is also one of the authors of the MEDAL study, says that he sees a great irony in the results.
Research by Garret Fitzgerald at the University of Pennsylvania, who had a decade ago warned about the potential heart risks of the arthritis drugs Vioxx and Celebrex, seemed to show such an effect was possible.
FORBES: Why Merck's Niacin Failure Will Scare Drug Researchers
The second editorial, by University of Pennsylvania cardiovascular researcher Garret FitzGerald , warns that it is very possible that other similar drugs, such as Pfizer 's (nyse: PFE - news - people ) Celebrex and Bextra, may also increase the risk of heart problems.
Garret A. FitzGerald, chair of pharmacology at the University of Pennsylvania and an early voice of concern about drugs like Vioxx, disagrees that there is any new information offered by the follow-up results.
All told, these studies might seem to provide evidence that Garret A. FitzGerald , a University of Pennsylvania researcher, was right when he theorized that inhibiting Cox-2 spares the stomach but increases the risk of heart attack.
Garret A. FitzGerald, a pharmacologist at the University of Pennsylvania, raised the first red flags about pharmaceuticals like Vioxx, Celebrex and Bextra after he saw chemical reasons that the drugs, which all inhibit inflammation by blocking the same enzyme, might cause heart attacks.
应用推荐